<DOC>
	<DOCNO>NCT01433289</DOCNO>
	<brief_summary>The purpose study determine safety , toxicity , dose , antiviral effect epigallocatechin gallate ( EGCG ) capsule form ( Polyphenon® E ) , administer orally twice daily three different dos HIV-1-infected clinically stable , treatment-naïve treatment-experienced adult concomitant antiretroviral ( ARV ) therapy .</brief_summary>
	<brief_title>Study Evaluate Safety Toxicity Polyphenon E ( EGCG ) HIV-1-Infected Individuals</brief_title>
	<detailed_description>HIV-1 infection ultimately result impair specific immune function virtue initial bind HIV-1 virion envelope glycoprotein 120 ( gp120 ) CD4 receptor complex chemokine receptor T-cell surface1 . Even though gp120 elicits virus-neutralizing antibody , HIV-1 elude immune system lead onset AIDS . Ever since discovery virus causative agent , intense effort develop therapeutic method inhibit prevent infection.2-4 CD4 , cell surface glycoprotein express T cell , play important role recognition antigens T cell activation.5 It also act receptor HIV-1 gp120 bind via D1 domain , use interaction infect CD4+ T cells.5 Therefore , interest finding molecule block bind gp120 CD4 ( entry inhibitor ) way reduce HIV-1 infectivity . Studies demonstrate evidence high affinity bind EGCG CD4 molecule Kd 10nM subsequent inhibition gp120 bind human CD4+ T cell . EGCG bind molecular pocket CD4 , HIV-1-gp120 physiologically relevant concentration . This phase I , placebo-controlled , dose-blinded , randomize study Polyphenon® E monotherapy participant HIV-1-infected CD+ T lymphocyte count least 250 cells/mm3 ARV-naïve ARV-experienced . There three treatment arm , consist 8 evaluable participant . Two participant study arm randomize receive placebo . Dosing escalate sequentially contingent safety profile previous dos . Safety data participant receive Polyphenon® E precede arm evaluate consider acceptable prior escalation next high dose . PK analyse also perform arm complete . If least 4 subject active drug arm evaluable PK data , subject replace . As inability achieve adequate EGCG concentration necessary inhibit HIV-1 replication major concern study , necessary confirm EGCG pharmacokinetics event primary outcome measure virologic response observe arm . For PK visit Study Days 1 14 , total 10 blood sample obtain per subject . If sample use ( depend individual subject 's pharmacokinetic profile , although one two unevaluable sample likely cause subject 's data unevaluable ) , PK analyse still perform require subject deem unevaluable replace .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>HIVinfected individual least two follow combination obtain 2 different sample : Positive HIV rapid test ELISA Western Blot ; HIV RNA PCR &gt; 10,000 copies/ml ; positive HIV DNA PCR ; neutralizable HIV p 24 antigen Asymptomatic HIV1 infect individual either antiretroviralnaive treatmentexperienced . Subjects must ARV treatment least 12 week prior enrollment plan start ARV treatment within 8 week study initiation . Male female 18 65 year age . Males must use barrier method contraception Females must willing abide protocol specify method avoid become pregnant . Women childbearing potential must use adequate form birth control determine investigator ( e.g. , oral contraceptive , doublebarrier method , hormonal injectable implanted contraceptive , tubal ligation , vasectomy ) . HIV1 RNA &gt; 1,000 copies/mL Screening . In opinion investigator , subject stable CD4+ T lymphocyte count ARV 250 cells/mm3 Screening . Participants clinically significant finding screen evaluation ( clinical , laboratory , EKG ) . Be able comprehend willing sign ICF . Be able comply protocol requirement . Have life expectancy &gt; 6 month . Laboratory value obtain screen must within normal limit meet following requirement ( Safety Labs ) : ANC 1000/mm3 Hemoglobin 9.0 g/dL Glucose ( nonfasting ) &lt; 116 mg/dL Bilirubin 1.5 x upper limit normal ( ULN ) Liver function test ( AST &amp; ALT ) 1.25 x ULN screen baseline GGT &lt; 5.0 x ULN Negative hepatitis panel obtain less equal 6 month prior Study Entry Creatinine 1.3 x ULN Creatine phosphokinase ( CPK ) 5 x ULN unless evaluation determines due exercise Urine protein 2+ Prothrombin time ( PT ) 1.25 x ULN Lipase 1.2 x ULN Current recent ( &lt; 3 month ) history opportunistic infection , Acute illness within 1 week baseline visit . Participant able comply dose schedule protocol evaluation . Participant anticipate begin ARV treatment participation study . Pregnancy , breastfeed postpartum ( le 3 month ) . Diagnosis diabetes . Any condition could compromise participant safety adherence protocol . Documented positive test hepatitis B surface antigen , hepatitis B surface antibody ( exception participant receive hepatitis B vaccination hepatitis B surface antibody ) , hepatitis B core antibody , hepatitis C antibody . Any grade 3 4 laboratory abnormality note screen accord DAIDS grade scale ( Appendix A ) , except follow : Grade 3 4 triglyceride elevation . Grade 3 cholesterol elevation . Grade 3 nonfasting glucose elevation . Participant malabsorption syndrome possibly affect drug absorption ( e.g . Crohn 's disease chronic pancreatitis ) . Participant receive HIV prophylactic therapeutic vaccination within 6 month prior first dose study medication . Investigational therapy within 30 day prior Baseline visit . Radiation therapy systemic cytotoxic chemotherapeutic agent within 12 week prior baseline visit recover side effect therapy prior first dose study medication . Positive urine screen drug abuse Screening , unless investigator deem result associate prescribed medication inhale use THC . Inability avoid tea/tea product ( include herbal , caffeinated , decaffeinate , iced tea ) , apple , chocolate , broad bean ( fava bean ) , plum , prune , cherry , fruit juice contain apple , cherry , plum , dietary supplement , herbal product 1 week prior baseline visit duration study . Inability limit caffeine intake exceed 12 oz . caffeinated beverage per day ( espresso , 1 oz . 1 shot ) begin 2 day prior duration study . Prior exposure TNX355 ( investigational antiHIV agent bind CD4+ T lymphocyte surface ) . Participant use proton pump inhibitor start 14 day Study Day 1 unable avoid take proton pump inhibitor duration study . Participant use H2 blocker start 24 hour Study Day 1 unable avoid take H2 blocker duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>safety</keyword>
	<keyword>toxicity</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Polyphenon E</keyword>
	<keyword>EGCG</keyword>
	<keyword>green tea</keyword>
	<keyword>CD4</keyword>
	<keyword>viral load</keyword>
</DOC>